Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Immutep has reset the development strategy for its lead immunotherapy eftilagimod alfa, or efti, concentrating future registration-directed work on two areas where management believes the clinical evidence and regulatory pathway are strongest.

The company now intends to focus on head and neck squamous cell carcinoma in patients with negative PD-L1 expression, defined as a Combined Positive Score below 1, and on efti in the neoadjuvant treatment of soft tissue sarcoma.

The narrowing follows the early discontinuation of the TACTI-004 study, an outcome that put both the clinical program and efti's manufacturing profile under considerable scrutiny. The important development for investors is that Immutep's investigation has so far identified differences between material manufactured at different production scales, while not finding clinical or trial execution factors that explain the unexpected result.

That is not the same as having a definitive explanation. The root cause analysis remains underway, and management has promised a further update once it is complete.

Manufacturing scale emerges as a key question

The investigation has identified structural differences between efti produced at the 200-litre scale and material manufactured at the 2,000-litre scale used exclusively in TACTI-004.

Among the differences identified is a subtle variation in N-glycan structure. Immutep considers this potentially relevant because TACTI-004 produced a markedly different immune activation profile from earlier studies and an unexpected clinical outcome.

The company has now contracted a fresh manufacturing run at the 200-litre scale. That scale has history behind it: 10 GMP batches were previously manufactured at 200 litres and used across successful Phase I and Phase II trials including TACTI-mel, TACTI-002 and INSIGHT-003.

For biotech investors, the distinction matters. Manufacturing consistency is not merely a factory-floor issue for biologic drugs. Changes in product characteristics can potentially affect biological activity, which makes resolving the scale-related differences important before Immutep commits substantial capital to another registration-directed study.

Management says the available evidence does not point to a suboptimal protocol, major treatment-arm imbalance, safety finding, invalid randomisation pattern or broader trial-conduct issue as the explanation for TACTI-004. That leaves manufacturing and pharmacological questions firmly under the microscope.

Head and neck cancer and sarcoma move to centre stage

The head and neck program will target patients with CPS below 1, a group characterised by limited approved treatment options and high unmet medical need. Immutep cites clinical efficacy data, including mature overall survival results, as support for pursuing this population.

Efti has also received Fast Track designation from the US Food and Drug Administration in first-line head and neck cancer. Management describes previous FDA feedback as constructive, adding regulatory weight to the decision to prioritise this setting.

The second priority is neoadjuvant soft tissue sarcoma. Here, Immutep is leaning on positive Phase II data that achieved its primary endpoint, together with Orphan Drug Designation granted by the FDA in April 2026.

The shift is therefore less about spreading efti across multiple tumour types and more about concentrating resources where the clinical signal, regulatory support and potential route to market appear most compelling.

Next trials targeted for the second half of 2027

Preparations for the next studies have begun, with Immutep targeting a start in the second half of calendar 2027.

That timetable comes with several caveats. Final trial design, regulatory discussions, manufacturing timelines, partnering arrangements and available resources all remain dependencies. The company specifically flags additional funding and the outcome of partnering discussions among the risks that could affect development.

Licensing partner Dr. Reddy's Laboratories has been consulted and supports the proposed approach. Immutep is also holding preliminary discussions with other parties regarding the development pathway, although no further detail has been provided.

Chief executive Marc Voigt said the company believes there remains "a scientifically and clinically justified path" for efti, pointing to evidence across multiple tumour types, immune activation data and encouraging results in sarcoma and CPS-negative head and neck cancer.

At the same time, Voigt acknowledged the significance of TACTI-004 and said the company intends to apply the lessons from its ongoing investigation "rigorously".

Investors now have a clearer set of milestones

The strategic reset gives investors a more concentrated list of issues to watch: completion of the root cause analysis, results from the new 200-litre manufacturing run, regulatory agreement on future trial design, funding and partnering progress, and whether the targeted 2027 clinical timetable remains achievable.

Meanwhile, Immutep's broader LAG-3 portfolio has not been shelved. Development of IMP761, its agonist anti-LAG-3 antibody targeting autoimmune disease, is continuing according to previously disclosed plans.

The immediate investment narrative, however, is squarely back on efti. The program has not returned to business as usual after TACTI-004. Instead, Immutep is taking a more selective route, with manufacturing comparability and regulatory alignment now just as important as the clinical data itself.

Adisyn has strengthened its intellectual property position in semiconductor graphene technology after the United States Patent and Trademark Office allowed a third US patent application, this time covering the deposition of graphene directly onto non-metallic surfaces.

The application, titled Method for Coating a Non-Metallic Surface with Graphene, extends the company's protection beyond the metallic surfaces covered by its earlier US patent allowances. The significance is that modern semiconductor interconnects contain both conductive metals and surrounding non-metallic dielectric materials, so Adisyn is progressively building protection across both sides of a critical interface.

The allowed claims cover a process using a graphene molecular precursor capable of forming a covalent bond directly with a non-metallic surface. Importantly for semiconductor manufacturing, the process maintains the underlying surface below 400°C, supporting Adisyn's broader strategy of developing low-temperature graphene deposition processes suitable for semiconductor environments.

Covering both sides of the interconnect

The commercial logic behind the patent becomes clearer when looking at how semiconductor interconnects are constructed.

Copper wiring carries electrical signals through a chip, while a barrier layer is used to prevent copper atoms migrating into the surrounding dielectric material. That dielectric material provides electrical insulation and is predominantly non-metallic.

Traditional barrier layers can use compounds such as tantalum nitride. Adisyn's technology is aimed at using graphene as an alternative barrier material.

The newly allowed claims protect the deposition of graphene onto the non-metallic dielectric surface, complementing earlier intellectual property covering graphene deposition onto metallic surfaces and resulting metal-based interconnect products.

This effectively gives Adisyn protection from two directions: graphene interacting with the conductive metal and graphene interacting with the surrounding dielectric.

That does not guarantee commercial adoption, of course, but from an intellectual property perspective it gives the company broader coverage around the architecture it ultimately hopes semiconductor manufacturers will use.

The battle against the semiconductor 'barrier tax'

The technical opportunity is driven by an increasingly awkward problem for advanced chipmakers.

As semiconductor architectures shrink below 5 nanometres, the available space for interconnect wiring becomes extremely constrained. Yet the barrier and dielectric materials surrounding those wires cannot simply disappear because they perform essential containment and insulation functions.

The result is what Adisyn describes as the "barrier tax" - a growing proportion of extremely valuable chip real estate being consumed by materials that protect the wiring rather than conduct electricity.

Graphene's potential attraction is its extreme thinness. Adisyn has previously demonstrated its ability to deposit graphene at approximately 1 nanometre thickness.

If graphene-based barriers can ultimately perform the required diffusion-barrier function at significantly reduced thickness, chip designers could potentially free up more space within increasingly cramped interconnect structures.

The latest claims specifically

KTEK Aerosystems has added another unmanned-aircraft program to its order book, securing a US$172,500 contract with Israel-based Vestal Technology to advance the structural design and manufacture two prototype airframes for Vestal's SCOOPER 25 electric UAV.

The dollar value is modest, but the more interesting investor angle is the scope of the work. KTEK is not simply manufacturing parts to an existing drawing. It will handle structural design development, engineering, tooling, structural analysis and prototype production, giving the company involvement across several stages of the aircraft development process.

That fits squarely with KTEK's strategy of winning customers early in a platform's development, with the possibility of remaining involved through prototyping, qualification and potentially serial production.

For now, though, investors should keep the distinction between possibility and contracted revenue firmly in view.

From design desk to prototype airframe

The contract covers the structural work required to take Vestal's SCOOPER 25 from preliminary design toward prototype-manufacturing maturity.

KTEK will complete the structural design required for prototype manufacture, produce the associated tooling, undertake static structural analysis and manufacture two composite prototype airframe structures.

The SCOOPER 25 is designed for a maximum take-off mass of up to 25 kilograms and is based on Vestal's patented SCOOP wing architecture. Vestal says the design is intended to generate high lift at low speeds, support extreme short take-off and landing operations and provide extended endurance with relatively low acoustic and thermal signatures.

Those characteristics are aimed at defence, special operations, intelligence and surveillance, mapping and infrastructure-monitoring markets.

The first prototype airframe is targeted for completion within five months of project commencement, with the second expected about one month later. Those timelines remain dependent on customer inputs, finalisation of the aircraft configuration and supplier availability.

Contract value is small, but the scope matters

At US$172,500, the initial contract is not the sort of deal that transforms a company's financial position overnight.

Its strategic relevance instead comes from demonstrating KTEK's full-turnkey design-to-build proposition.

Rather than competing only as a component manufacturer, KTEK is positioning itself further upstream in aerospace development programs, where engineering expertise, tooling capability and structural design can help establish a supplier relationship before a platform enters production.

Managing director Dekel Keisar described the contract as a strong example of that model, saying KTEK was combining "structural engineering, composite design, tooling and manufacturing capabilities" to help move the SCOOPER 25 from preliminary design into physical prototypes.

That broader capability potentially gives KTEK more ways to generate revenue from a program than a pure manufacturing relationship would.

Revenue from the Vestal contract is expected to be recognised progressively as engineering, tooling and prototype milestones are completed, rather than appearing as a single lump sum.

The real prize would be follow-on production

The key issue for investors is what happens after the two prototypes are delivered.

KTEK's business model is based partly on entering customer programs during development and then potentially following those programs into qualification, serial manufacture and spares.

Vestal therefore represents a new customer with potential strategic value beyond the first contract.

Keisar said the agreement provides KTEK with "an opportunity to remain involved as the platform progresses", while stressing that the immediate priority is successfully delivering the two contracted prototype structures.

That qualification matters.

There is currently no commitment for serial production, no contracted follow-on manufacturing volume and no guarantee that the SCOOPER 25 will progress to larger commercial orders. Any additional work would depend on successful prototype development, Vestal's future requirements and a separate commercial agreement.

In other words, investors should treat the US$172,500 as the contracted opportunity and any production upside as optionality rather than forecast revenue.

Another test of the Cordless Factory model

The program also provides another practical test of KTEK's "Cordless Factory" operating model.

The company keeps engineering design, structural analysis, program management and quality assurance in-house while using a network of certified international manufacturing partners. The aim is to scale production without carrying the capital burden of a traditional large aerospace manufacturing footprint.

Prototype programs such as SCOOPER 25 suit that model because they require substantial engineering and project-management capability before manufacturing volumes become large.

If customers subsequently move into serial production, KTEK's challenge is to show that its partner-based manufacturing structure can scale efficiently while maintaining aerospace quality standards and delivery discipline.

Delivery now becomes the key milestone

The immediate catalysts are operational rather than promotional.

KTEK and Vestal will finalise the aircraft configuration and design-load basis before progressing engineering, tooling and prototype manufacture. Delivery of the first prototype within the targeted five-month period would provide evidence that KTEK can execute the complete design-to-build process on schedule.

From an investor perspective, the contract is best viewed as a small but strategically relevant customer win.

The initial revenue contribution is limited, but the program broadens KTEK's customer base and puts its engineering-led aerospace model to work on another UAV platform. The more consequential development would be successful prototype delivery followed by a move into larger-volume manufacturing.

Until then, the value of the Vestal relationship lies less in the size of the first cheque and more in whether KTEK can turn prototype work into a longer production relationship.

Osteopore has added Thailand to its regional growth map, securing market access for its full orthopaedic product range and putting in place the logistics infrastructure needed to supply hospitals and clinics.

For investors, the significance is less about an immediate revenue windfall and more about removing two important barriers to commercialisation: regulatory market access and a functioning local supply chain. Thailand is a sizeable healthcare market, and Osteopore now has the ability to begin converting that opportunity into hospital listings, surgeon adoption and, ultimately, sales.

Thailand brings scale to the regional strategy

The numbers explain why Thailand has attracted Osteopore's attention.

The country's orthopaedic devices market was valued at approximately US$749 million in 2025 and is projected to reach around US$1.5 billion by 2033. That represents compound annual growth of 9.2%, which the company says places Thailand among the fastest-growing orthopaedic markets in the Asia-Pacific region.

Osteopore is not targeting that entire market. Its regenerative scaffolds sit within the bone-repair orthobiologics and bone graft substitutes segment, which the company estimates typically accounts for about 8% to 10% of total orthopaedic device spending.

On that basis, management puts its relevant addressable market in Thailand at approximately US$60 million to US$80 million annually.

That is an addressable market figure rather than a revenue forecast, an important distinction for investors. Osteopore has not provided sales guidance, expected market share, pricing assumptions or a timetable for meaningful commercial revenue from Thailand.

Still, for a comparatively small medical technology company, gaining access to a market of that potential size broadens the commercial runway materially.

Auriga partnership tackles the less glamorous part of medtech

Regulatory approvals tend to attract the headlines, but medical devices do not sell themselves once they cross the border.

Osteopore has partnered with healthcare market management group DCH Auriga, which will act as its market authorisation holder in Thailand. Auriga will also import Osteopore's devices and supply hospitals and clinics as directed by the company.

That arrangement gives Osteopore an established local logistics and market-management platform rather than requiring it to build an entire distribution network from scratch.

Auriga has operated in Asian healthcare markets for more than 50 years and says it distributes more than 500 brands across more than 10,000 points of sale. Its operations extend across Thailand and numerous other Asian markets, including Singapore, Malaysia, Vietnam, Indonesia, the Philippines, Hong Kong and mainland China.

For investors, the partnership is noteworthy because execution is often where overseas medtech expansion becomes expensive and slow. Having an experienced operator handling authorisation, imports and distribution should simplify the route from regulatory access to actual hospital supply.

It does not, however, eliminate the commercial challenge of winning surgeons, procurement committees and hospital budgets.

Hospital listings are now the key milestone

The next stage is much more tangible: Osteopore plans to pursue product listings with targeted public and private hospitals in Bangkok.

That is where investors will get a clearer sense of whether regulatory access translates into demand.

Osteopore's range includes its flagship product for medial opening wedge high tibial osteotomy procedures, while its broader technology uses 3D-printed, bioresorbable scaffolds designed to support natural bone regeneration before gradually dissolving.

Management points to several structural drivers supporting Thailand's orthopaedic market, including wider access to reconstructive procedures through universal healthcare, an increasing burden of orthopaedic disease and significant trauma-related demand.

Those factors create a potentially attractive backdrop, but the commercial evidence investors will want next is straightforward: hospital listings, clinician adoption, orders and recurring revenue.

Another step in Osteopore's ASEAN push

Chief executive Dr Yujing Lim described Thailand as one of Osteopore's key ASEAN markets and said the company was "smoothly executing on our regional expansion plans".

He also noted that Osteopore has been presenting its regenerative technology at meetings and conferences ahead of more formal commercial engagements.

The Thailand move therefore looks less like an isolated regulatory win and more like another piece of a broader Asian expansion strategy.

The attraction is clear. Osteopore has proprietary 3D-printing technology, a bioresorbable product platform and now access to a sizeable, fast-growing orthopaedic market supported by an established healthcare logistics partner.

The missing ingredient, for now, is revenue visibility.

Securing market access gets Osteopore through the front door. Hospital listings and commercial orders will determine whether Thailand becomes a meaningful contributor rather than simply another pin on the regional map. For investors watching the company's expansion, those are the milestones that should now carry the most weight.

Adisyn has made a decisive change at the top as it attempts to shift from technology development into commercial execution, with the board restructuring leadership around its semiconductor ambitions and commencing a search for a new industry-experienced chief executive.

The company has moved Arye Kohavi from Managing Director to Non-Executive Director with immediate effect, while also confirming it will not support an extension of his service agreement as chief executive of 2D Generation beyond its current term ending 9 January 2027.

Former Non-Executive Chairman Kevin Crofton has stepped into the Executive Chairman role, giving him direct oversight of Adisyn's strategic, technical and commercial priorities during the transition.

The changes amount to more than a routine boardroom reshuffle. They signal that Adisyn believes its next challenge is no longer simply proving the potential of its graphene technology, but finding the leadership required to convert technical progress and industry engagement into commercial outcomes.

Commercialisation becomes the priority

Adisyn's core technology proposition centres on a patented low-temperature Atomic Layer Deposition process designed to enable direct graphene growth on semiconductor wafers.

The company is targeting a potentially significant problem for the semiconductor industry: the performance limitations of copper interconnects as semiconductor devices continue to shrink and computational demands increase.

Management says Adisyn has made substantial progress in establishing its semiconductor technology platform, expanding its graphene technology portfolio and increasing engagement with global semiconductor industry participants.

That progress now appears to have prompted a change in emphasis.

The board says its strategic priority is to accelerate commercial execution and recruit leadership with extensive semiconductor experience and a demonstrated record of turning technology into partnerships and business growth.

For investors, that distinction matters. Technology companies can spend years demonstrating technical promise, but value creation ultimately depends on moving beyond laboratory or development milestones into commercial validation, partnerships, licensing, manufacturing adoption or revenue.

Adisyn is effectively acknowledging that the skills required for the next phase may differ from those that helped build the technology platform.

Crofton provides continuity

Kevin Crofton's appointment as Executive Chairman gives Adisyn an experienced operator while the chief executive search proceeds.

Crofton brings more than three decades of international experience across semiconductors, advanced manufacturing and technology. He will also remain a director of both 2D Generation and 2D Radar Absorbers.

Importantly, his remuneration will not change at this stage despite the expanded responsibilities, with the company framing the move as support during the leadership transition.

Crofton said the board believed the timing was appropriate to evolve Adisyn's leadership structure as the company moved from technology development towards commercial execution.

He said the immediate focus would be maintaining continuity while securing a chief executive with semiconductor industry experience and a track record across technology commercialisation, strategic partnerships and business growth.

The board intends to complete the recruitment process in a timely manner, although no specific appointment timetable has been provided.

A broader graphene opportunity

While semiconductor technology remains the central strategic focus, Adisyn is also applying its graphene expertise in other fields.

The company is exploring advanced composite materials intended to reduce radar signatures in unmanned aerial vehicles and defence platforms, giving it exposure to another potentially high-value application for graphene-based materials.

Adisyn also retains its managed technology services business, which provides IT, cloud, cybersecurity and artificial intelligence services to Australian small and medium-sized businesses.

However, the leadership changes make clear where the board sees the larger strategic opportunity. Semiconductor commercialisation is now at the centre of the story.

What investors will be watching

The next major test will be the calibre of the chief executive Adisyn attracts and whether that appointment can translate industry engagement into tangible commercial milestones.

Investors will also be looking for evidence that semiconductor discussions progress towards partnerships, technology qualification, customer validation or other commercially meaningful agreements.

The leadership transition does not itself change the underlying technical proposition. What it changes is the company's approach to converting that proposition into a business.

Adisyn has spent considerable effort building its graphene technology base. The board is now signalling that the next phase requires a different emphasis - less about establishing the platform and more about proving that global semiconductor interest can ultimately become commercial traction.

That makes the chief executive search one of Adisyn's most important near-term corporate milestones, and potentially a defining step in determining whether its graphene technology can move from promise to commercial relevance.